The Artificial Intelligence in Precision Medicine Market is entering a high-growth phase as healthcare providers and pharmaceutical companies increasingly use AI to understand disease biology, predict treatment responses, and develop therapies tailored to individual patients. Artificial Intelligence in Precision Medicine Market Valued at USD 2.4 billion in 2025, the market is projected to increase from USD 3.4 billion in 2026 to USD 32.5 billion by 2033, expanding at a CAGR of 38.3% from 2026 to 2033.

The shift toward personalized healthcare is changing how diseases are diagnosed, monitored, and treated. Instead of relying exclusively on standardized treatment protocols, precision medicine combines patient-specific information with advanced analytical technologies to support more targeted clinical decisions. AI strengthens this approach by identifying patterns across genomic, molecular, imaging, and clinical datasets that may be difficult to detect through conventional analysis.

Market Snapshot: Four Signals Defining Growth

• Market valuation: USD 2.4 billion in 2025.
• Forecast trajectory: USD 32.5 billion by 2033.
• Leading technology: Deep learning, with a 33.5% share in 2025.
• Leading component: Software, accounting for 42.0% of revenue in 2025.
• Leading therapeutic application: Oncology, representing 30.0% of the market in 2025.
• Regional leadership: North America held 53.3% of revenue in 2025, while Asia Pacific is expected to record the fastest CAGR during the forecast period.

These indicators highlight a market where software innovation, computational capabilities, and demand for targeted treatment are advancing together.

Where AI Creates the Greatest Clinical Value

The value of artificial intelligence in precision medicine extends beyond faster data processing. Its significance lies in translating complex biological information into insights that can support clinical research and treatment decisions.

Cancer care illustrates this potential. The growing need for accurate diagnosis, biomarker identification, and patient selection has increased interest in AI-powered oncology solutions. According to GLOBOCAN 2022, approximately 10 million cancer deaths occurred worldwide in 2022, reinforcing the importance of improving diagnostic and treatment approaches.

Download a free sample report or claim your copy of this full market intelligence report

In January 2024, researchers at Penn Medicine developed iStar, an AI tool capable of analyzing gene activity in medical images. The technology can identify tertiary lymphoid structures associated with potential survival outcomes and favorable responses to immunotherapy. Such capabilities may help researchers identify patients more likely to benefit from particular treatments.

Beyond oncology, neurological disorders are creating additional opportunities. AI-assisted imaging and data analysis can support the investigation of complex conditions, including Alzheimer's and Parkinson's diseases. The neurology segment is expected to record the fastest growth among therapeutic applications as demand for earlier diagnosis and more personalized interventions increases.

Technology Is Changing How Patient Data Is Interpreted

Different AI technologies contribute distinct capabilities to precision medicine, with their adoption influenced by the complexity and type of healthcare information being analyzed.

Deep learning remains the technology leader. Holding 33.5% of the market in 2025, it supports the analysis of complex datasets and the integration of information collected across different modalities and time periods. In May 2023, GE HealthCare received FDA 510(k) clearance for Precision DL, a deep learning-based image-processing software designed to improve image quality and quantitative accuracy.

Natural language processing is expanding data accessibility. Healthcare information is frequently recorded in clinical documents and other unstructured formats. NLP can help extract relevant insights from these records, supporting more efficient clinical decision-making. In November 2023, GenomOncology announced that City of Hope would enhance its NLP pipeline using HopeIQ, a data enablement solution powered by GenomOncology's igniteIQ platform.

Software provides the operational foundation. With a 42.0% market share in 2025, software represented the largest component segment and is also expected to grow rapidly. In June 2023, Illumina introduced PrimateAI-3D, an AI algorithm designed to predict disease-causing genetic mutations, with plans for broader accessibility through Illumina Connected Software.

Hardware also matters because advanced AI applications require substantial computational power. Insilico introduced PandaOmics Box in July 2024, combining AI-driven research software, scientific databases, and high-performance computing capabilities to support drug discovery and personalized medicine research.

The Data Infrastructure Behind Personalized Treatment

The expansion of electronic health records, digital pathology, genomics, and wearable devices is increasing the volume of information available for precision medicine.

Wearables can capture physiological changes and support continuous disease monitoring. When combined with AI and machine learning, these data streams can help identify anomalies, assess medication adherence, and inform preventive care.

Digital pathology is another important development. In September 2024, Roche expanded its digital pathology platform by integrating more than 20 AI algorithms from eight new partners. The initiative aims to provide researchers and pathologists with additional analytical capabilities for cancer research and diagnosis.

Collaborations are also strengthening the connection between technology and clinical practice. Enlitic collaborated with GE Healthcare in August 2022 to help picture archiving and communication system (PACS) users improve workflow efficiency through data standardization using Enlitic Curie.

However, access to large datasets alone is insufficient. Data quality, interoperability, security, and the ability to integrate AI outputs into clinical workflows remain important considerations for effective implementation.

Key Companies

The companies identified in the supplied market information include:

• BioXcel Therapeutics Inc.
• Sanofi
• NVIDIA Corporation
• Alphabet Inc. (Google Inc.)

Competitive activity also involves partnerships between healthcare organizations, research institutions, and technology developers. In May 2021, AdventHealth collaborated with Sema4 to integrate genomic and clinical data through software platforms and tools, supporting its personalized health and genomics initiatives.

Explore the full list of profiled companies operating in this market with recent strategic initiatives

Regional Competition: Established Infrastructure Meets New Investment

North America accounted for 53.3% of global market revenue in 2025. Its position is supported by healthcare technology development, substantial research investment, and collaborations between medical institutions and technology companies. The United States held the largest country-level market share in 2025.

Asia Pacific is expected to register the fastest CAGR during 2026–2033. Rising healthcare AI investment, demand for personalized treatments, and government initiatives promoting healthcare innovation are supporting regional adoption. Japan's healthcare infrastructure and research investment also create opportunities for AI applications targeting age-related and chronic diseases.

Europe is another important market, with digital health initiatives and efforts to improve access to oncology data supporting innovation. The European Cancer Imaging Initiative seeks to facilitate the use of large-scale oncology imaging data for improved cancer detection, diagnosis, and treatment development.

Market Outlook: From Data Analysis to Treatment Decisions

The artificial intelligence in precision medicine market is positioned for substantial expansion as healthcare increasingly prioritizes targeted therapies, earlier disease detection, and evidence-based treatment selection. The projected rise to USD 32.5 billion by 2033 reflects growing interest in technologies that can convert complex patient information into actionable insights.

Long-term opportunities will depend on the ability to develop reliable algorithms, establish strong research partnerships, maintain high-quality data, and meet regulatory requirements. Companies that combine AI expertise with clinically relevant datasets and scalable infrastructure may be better positioned to participate in this evolving healthcare landscape.

Explore Our Research & Intelligence Solutions

Prism AI: Ask. Analyze. Get Cited Market Insights. – Explore Now

Grand View Signal: Understand the Factors Shaping Commodity Prices – Explore the Platform